Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GLAUKOS CORPORATION Glaukos Corporation Stock price
Equities
GKOS
US3773221029
Medical Equipment, Supplies & Distribution
| Delayed Nyse 04:00:01 2023-09-22 pm EDT |
|
5-day change | 1st Jan Change | |
| 75.28 USD | +0.04% | +0.21% | +72.34% | |
| Sep. 08 | Stephens Adjusts Glaukos Price Target to $93 From $90, Maintains Overweight Rating | MT |
| Aug. 03 | Mizuho Adjusts Price Target on Glaukos to $85 From $80, Maintains Neutral Rating | MT |
Financials (USD)
| Sales 2023 * | 307 M | Sales 2024 * | 347 M | Capitalization | 3 659 M |
|---|---|---|---|---|---|
| Net income 2023 * | -124 M | Net income 2024 * | -103 M | EV / Sales 2023 * | 12,6x |
| Net Debt 2023 * | 193 M | Net Debt 2024 * | 196 M | EV / Sales 2024 * | 11,1x |
| P/E ratio 2023 * | -29,4x | P/E ratio 2024 * | -34,9x | Employees | - |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 96.07% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.69% | ||
| 1 week | -0.25% | ||
| Current month | +0.15% | ||
| 1 month | +3.18% | ||
| 3 months | +15.93% | ||
| 6 months | +52.73% | ||
| Current year | +72.28% |
1 week
74.78
78.07
1 month
71.6178.95
Current year
42.4880.28
1 year
40.4580.28
3 years
33.3399.00
5 years
23.3199.00
10 years
14.2599.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Burns
CEO | Chief Executive Officer | 62 | 2000 |
| President | 47 | 2022 | |
Alex Thurman
DFI | Director of Finance/CFO | 53 | 2022 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Burns
CHM | Chairman | 62 | 2021 |
Mark Foley
BRD | Director/Board Member | 57 | 2014 |
Gilbert Kliman
BRD | Director/Board Member | 64 | 2006 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 457 M$ | +2.48% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-22 | 75.28 | +0.04% | 486 204 |
| 23-09-21 | 75.25 | -0.69% | 580,966 |
| 23-09-20 | 75.77 | -1.04% | 645,123 |
| 23-09-19 | 76.57 | +1.38% | 614,987 |
| 23-09-18 | 75.53 | +0.55% | 198,917 |
Delayed Quote Nyse, September 21, 2023 at 04:00 pm EDT
More quotes
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. The Company is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Calendar
2023-11-07
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
75.25USD
Average target price
83.20USD
Spread / Average Target
+10.56%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +72.28% | 3 659 M $ | |
| -3.06% | 2 830 M $ | |
| -11.37% | 2 797 M $ | |
| +3.37% | 2 492 M $ | |
| -45.54% | 1 952 M $ | |
| -4.73% | 1 837 M $ | |
| -6.74% | 1 737 M $ | |
| -24.09% | 5 609 M $ | |
| -1.22% | 1 257 M $ | |
| +9.76% | 1 212 M $ |
